Lucid Diagnostics (LUCD) Common Equity (2022 - 2025)
Historic Common Equity for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to $25.8 million.
- Lucid Diagnostics' Common Equity rose 30762.07% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.8 million, marking a year-over-year increase of 30762.07%. This contributed to the annual value of $5.4 million for FY2024, which is 33327.56% up from last year.
- Per Lucid Diagnostics' latest filing, its Common Equity stood at $25.8 million for Q3 2025, which was up 30762.07% from $7.9 million recorded in Q2 2025.
- In the past 5 years, Lucid Diagnostics' Common Equity registered a high of $46.5 million during Q1 2022, and its lowest value of -$5.4 million during Q1 2025.
- Moreover, its 4-year median value for Common Equity was $15.1 million (2023), whereas its average is $16.1 million.
- Per our database at Business Quant, Lucid Diagnostics' Common Equity surged by 33327.56% in 2024 and then crashed by 14520.77% in 2025.
- Quarter analysis of 4 years shows Lucid Diagnostics' Common Equity stood at $23.0 million in 2022, then plummeted by 110.03% to -$2.3 million in 2023, then skyrocketed by 333.28% to $5.4 million in 2024, then soared by 379.22% to $25.8 million in 2025.
- Its Common Equity was $25.8 million in Q3 2025, compared to $7.9 million in Q2 2025 and -$5.4 million in Q1 2025.